Company intelligence / Profile preview

TheRas, Inc.

Palo Alto, California, United Statesbridgebiooncology.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has two drug candidates in Phase 1 clinical trials: BBO-8520 targeting KRAS G12C for metastatic non-small cell lung cancer and BBO-10203 targeting PI3Kα for locally advanced malignant solid neoplasm. A third candidate, BBP-454 targeting KRAS for neoplasms, is pending clinical trials.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

LNL

Unknown

Beyond the preview

Go deeper on TheRas, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheRas, Inc..

Explore the full profile